[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
January 2016

Epidemiology and Treatment of Eosinophilic FasciitisAn Analysis of 63 Patients From 3 Tertiary Care Centers

Author Affiliations
  • 1Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts
  • 2The Ronald O. Perelman Department of Dermatology, New York University Langone Medical Center, New York
JAMA Dermatol. 2016;152(1):97-99. doi:10.1001/jamadermatol.2015.3648

Eosinophilic fasciitis (EF) is a rare fibrosing disorder of the fascia characterized by erythema, edema, and induration of the bilateral extremities. Joint contractures and related functional limitation commonly occur owing to fascial involvement overlying the joints. Hematologic abnormalities, including peripheral eosinophilia and monoclonal gammopathy, may occur. Systemic corticosteroids are considered first-line therapy; however, prolonged treatment is frequently required in patients with EF, and a standardized therapeutic protocol is lacking.1,2 Given the dearth of systematic data guiding treatment, we evaluated the presentation and clinical response of EF in 63 patients at 3 tertiary care centers.

First Page Preview View Large
First page PDF preview
First page PDF preview